Horizon buying Vidara for Actimmune, Irish HQ
This article was originally published in Scrip
Executive Summary
Horizon Pharma believes that it will become even more profitable than expected this year after the company closes its $600m acquisition of Vidara Therapeutics in mid-2014 and adds Vidara's roughly $60m in annual Actimmune (interferon gamma-1b) revenue to its balance sheet.